Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Hypoalbuminemia in children with cancer treated with chemotherapy.

McLean TW, Stewart RM, Curley TP, Dewsnup MY, Thomas SG, Russell TB, Tooze JA.

Pediatr Blood Cancer. 2020 Feb;67(2):e28065. doi: 10.1002/pbc.28065. Epub 2019 Nov 17.

PMID:
31736232
2.

Modeling Framework Used to Analyze and Describe Junctional Tourniquet Skills.

Bauchwitz BR, Curley T, Kwan C, Niehaus JM, Pugh CM, Weyhrauch PW.

Mil Med. 2019 Mar 1;184(Suppl 1):347-360. doi: 10.1093/milmed/usy348.

PMID:
30901425
3.

Weight Bias in Pediatric Inpatient Care.

Halvorson EE, Curley T, Wright M, Skelton JA.

Acad Pediatr. 2019 Sep - Oct;19(7):780-786. doi: 10.1016/j.acap.2019.02.005. Epub 2019 Feb 21.

PMID:
30796998
4.

A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.

Graham L, Banda K, Torres A, Carver BS, Chen Y, Pisano K, Shelkey G, Curley T, Scher HI, Lotan TL, Hsieh AC, Rathkopf DE.

Invest New Drugs. 2018 Jun;36(3):458-467. doi: 10.1007/s10637-018-0578-9. Epub 2018 Mar 6.

5.

Nutrition Knowledge and Practices of Varsity Coaches at a Canadian University.

Danaher K, Curley T.

Can J Diet Pract Res. 2014 Dec;75(4):210-3. doi: 10.3148/cjdpr-2014-021.

PMID:
26067076
6.

Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.

Delacruz A, Arauz G, Curley T, Lindo A, Jensen T.

Clin J Oncol Nurs. 2015 Apr;19(2):E31-5. doi: 10.1188/15.CJON.E31-E35.

PMID:
25840395
7.

A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.

Iyer G, Morris MJ, Rathkopf D, Slovin SF, Steers M, Larson SM, Schwartz LH, Curley T, DeLaCruz A, Ye Q, Heller G, Egorin MJ, Ivy SP, Rosen N, Scher HI, Solit DB.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1089-97. doi: 10.1007/s00280-011-1789-3. Epub 2011 Nov 29.

8.

Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.

Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI.

Eur Urol. 2009 Aug;56(2):237-44. doi: 10.1016/j.eururo.2009.03.073. Epub 2009 Apr 3.

9.

Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.

Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, Larson S, Scher HI.

J Clin Oncol. 2009 May 20;27(15):2436-42. doi: 10.1200/JCO.2008.20.4164. Epub 2009 Apr 13. Erratum in: J Clin Oncol. 2011 Oct 10;29(29):3947-8.

10.

Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.

Rathkopf D, Carducci MA, Morris MJ, Slovin SF, Eisenberger MA, Pili R, Denmeade SR, Kelsen M, Curley T, Halter M, Collins C, Fleisher M, Heller G, Baker SD, Scher HI.

J Clin Oncol. 2008 Jun 20;26(18):2959-65. doi: 10.1200/JCO.2007.15.1928.

11.

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, Rosen N, Scher HI.

Clin Cancer Res. 2007 Mar 15;13(6):1775-82.

12.

Rapid androgen cycling as treatment for patients with prostate cancer.

Feltquate D, Nordquist L, Eicher C, Morris M, Smaletz O, Slovin S, Curley T, Wilton A, Fleisher M, Heller G, Scher HI.

Clin Cancer Res. 2006 Dec 15;12(24):7414-21.

13.

Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.

Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, Kelly WK.

Clin Lung Cancer. 2006 Jan;7(4):257-61.

PMID:
16512979
14.

Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.

Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, Smith-Jones P, Schwartz L, Kelly WK, Slovin S, Solit D, Halpern J, Delacruz A, Curley T, Finn R, O'donoghue JA, Livingston P, Larson S, Scher HI.

Clin Cancer Res. 2005 Oct 15;11(20):7454-61.

15.

The role of statins in chronic kidney disease.

Agarwal R, Curley TM.

Am J Med Sci. 2005 Aug;330(2):69-81. Review.

PMID:
16103787
16.

A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy.

Agarwal R, Saha C, Battiwala M, Vasavada N, Curley T, Chase SD, Sachs N, Semret MH.

Kidney Int. 2005 Jul;68(1):285-92.

17.

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM.

J Clin Oncol. 2005 Jun 10;23(17):3923-31. Epub 2005 May 16.

18.

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK.

J Clin Oncol. 2005 Mar 1;23(7):1439-46.

PMID:
15735119
19.

High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.

Morris MJ, Smaletz O, Solit D, Kelly WK, Slovin S, Flombaum C, Curley T, Delacruz A, Schwartz L, Fleisher M, Zhu A, Diani M, Fallon M, Scher HI.

Cancer. 2004 May 1;100(9):1868-75.

20.

Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.

Solit DB, Morris M, Slovin S, Curley T, Schwartz L, Larson S, Kattan MW, Hartley-Asp B, Scher HI, Kelly WK.

Cancer. 2003 Nov 1;98(9):1842-8.

21.

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88.

22.

Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.

Kelly WK, Zhu AX, Scher H, Curley T, Fallon M, Slovin S, Schwartz L, Larson S, Tong W, Hartley-Asp B, Pellizzoni C, Rocchetti M.

Clin Cancer Res. 2003 Jun;9(6):2098-107.

23.

Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial.

Verbel DA, Kelly WK, Smaletz O, Regan K, Curley T, Heller G, Scher HI.

Urology. 2003 Jan;61(1):142-4.

PMID:
12559285
24.

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

Kelly WK, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small EJ, Schwartz L, Larson S, Tong W, Scher H.

J Clin Oncol. 2001 Jan 1;19(1):44-53.

PMID:
11134194
25.

The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer.

Kelly WK, Osman I, Reuter VE, Curley T, Heston WD, Nanus DM, Scher HI.

Clin Cancer Res. 2000 Mar;6(3):838-46.

26.

Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer.

Graham MC, Scher HI, Liu GB, Yeh SD, Curley T, Daghighian F, Goldsmith SJ, Larson SM.

Clin Cancer Res. 1999 Jun;5(6):1307-18.

27.

Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.

Kelly WK, Scher HI, Mazumdar M, Pfister D, Curley T, Leibertz C, Cohen L, Vlamis V, Dnistrian A, Schwartz M.

J Clin Oncol. 1995 Sep;13(9):2214-22.

PMID:
7666079
28.

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.

Kelly WK, Curley T, Leibretz C, Dnistrian A, Schwartz M, Scher HI.

J Clin Oncol. 1995 Sep;13(9):2208-13.

PMID:
7545218
29.

Whole systems shared governance: a model for the integrated health system.

Evan K, Aubry K, Hawkins M, Curley TA, Porter-O'Grady T.

J Nurs Adm. 1995 May;25(5):18-27.

PMID:
7730930
30.

Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications.

Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang ZF, Rosai J.

J Clin Oncol. 1995 May;13(5):1195-200.

PMID:
7537803
31.

Executives share their first-class ideas.

Hawkins M, Curley T.

Aspens Advis Nurse Exec. 1995 Mar;10(6):7. No abstract available.

PMID:
7696011
32.

Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons.

Mitchel JF, Azrin MA, Fram DB, Hong MK, Wong SC, Barry JJ, Bow LM, Curley TM, Kiernan FJ, Waters DD, et al.

Circulation. 1994 Oct;90(4):1979-88.

PMID:
7923688
33.

Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC.

Scher HI, Geller NL, Curley T, Tao Y.

J Clin Oncol. 1993 Mar;11(3):400-7.

PMID:
8445414
34.

Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.

Seidman AD, Scher HI, Gabrilove JL, Bajorin DF, Motzer RJ, O'Dell M, Curley T, Dershaw DD, Quinlivan S, Tao Y, et al.

J Clin Oncol. 1993 Mar;11(3):408-14.

PMID:
7680373
35.

Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.

Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T.

J Urol. 1992 Mar;147(3 Pt 2):931-4.

PMID:
1371564
36.

Therapeutic alternatives for hormone-refractory prostatic cancer.

Scher HI, Curley T, Yeh S, Iversen JM, O'Dell M, Larson SM.

Semin Urol. 1992 Feb;10(1):55-64. Review.

PMID:
1373515
37.

Use of adaptive control with feedback to individualize suramin dosing.

Scher HI, Jodrell DI, Iversen JM, Curley T, Tong W, Egorin MJ, Forrest A.

Cancer Res. 1992 Jan 1;52(1):64-70.

38.

Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.

Scher HI, Curley T, Yeh S, Tong W, O'Moore PV, Larson S.

Adv Exp Med Biol. 1992;324:115-29. Review. No abstract available.

PMID:
1283494
39.

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.

Scher HI, Curley T, Geller N, Engstrom C, Dershaw DD, Lin SY, Fitzpatrick K, Nisselbaum J, Schwartz M, Bezirdjian L, et al.

J Clin Oncol. 1990 Nov;8(11):1830-8.

PMID:
1700078
40.

Neoadjuvant chemotherapy for bladder cancer: the MSKCC experience.

Fair WR, Scher H, Herr H, Morse M, Sogani P, Bosi G, Dershaw D, Reuter V, Curley T, et al.

Semin Urol. 1990 Aug;8(3):190-6. No abstract available. Erratum in: Semin Urol 1990 Nov;8(4):297. Bosh G [corrected to Bosi G].

PMID:
2399387
41.

Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single dose and fractionated regimens.

Zelefsky MJ, Scher HI, Forman JD, Linares LA, Curley T, Fuks Z.

Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1281-5.

PMID:
2480941
42.

Phase I clinical trial of doxorubicin and iproplatin combination chemotherapy in patients with breast cancer.

Casper ES, Curley T, Hakes TB.

Invest New Drugs. 1989 Jul;7(2-3):189-93.

PMID:
2793371
43.

Gallium nitrate in prostatic cancer: evaluation of antitumor activity and effects on bone turnover.

Scher HI, Curley T, Geller N, Dershaw D, Chan E, Nisselbaum J, Alcock N, Hollander P, Yagoda A.

Cancer Treat Rep. 1987 Oct;71(10):887-93.

PMID:
3308078

Supplemental Content

Loading ...
Support Center